Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Active, not recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

active_not_recruiting267%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
completed

Studying Pathways of Resistance in KRAS-driven Cancers

NCT05272423
active_not_recruitingnot_applicable

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

NCT06068075
active_not_recruitingnot_applicable

PRecision Oncology Evidence Development in Cancer Treatment - Liquid

NCT05057234

Clinical Trials (3)

Showing 3 of 3 trials
NCT05272423

Studying Pathways of Resistance in KRAS-driven Cancers

Completed
NCT06068075Not Applicable

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Active Not Recruiting
NCT05057234Not Applicable

PRecision Oncology Evidence Development in Cancer Treatment - Liquid

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3